Statistical analysis
Pooled analyses were performed using Stata 12.1 software (StataCorp College Station, TX, USA). To measure the association between exposure to biologics or classic systemic therapies and a priori defined variables, differences in means between groups were used for continuous variables, and odds ratios (OR) for categorical variables. To pool data from registries, forest plots were used and a random-effects meta-analysis was conducted to describe differences among groups exposed to biologics or conventional therapies. Pooled estimates of effects were produced if results were not too heterogeneous (I 2 < 60%). Some registries were not able to provide data on all of the defined variables. Due to the lack of enrolment of patients receiving classic systemic therapy, AMC psoriasis registry data were not included in the forest plots and in comparisons of exposure cohorts. In all the other registries, if a patient began in the non-biological therapy group and subsequently received a biologic drug, his or her characteristics contributed to both groups in the analysis.
RESULTS
From the start of each registry to August 2012, a total of 20,232 patients had been enrolled in the registries and provided baseline information. This included 9,668 (47.8%) initially treated with biologics and 10,564 (52.2%) starting classic systemic therapies.
Demographic and disease characteristics are summarized in Tables SII and SIII   1 . Some differences between patients receiving biologics and those receiving classic drugs were homogeneous between registries (I 2 ≤ 60%). These are presented in forest plots in Fig. 1 , which includes I 2 values, and pooled estimates. Overall, patients on biologics were 0.42 units of body mass index (BMI) heavier than those on classic systemic drugs (95% CI: 0.25-0.58). The OR of males vs. females receiving biologics was 1.08 (95% CI: 0.94-1.24). Use of biologics was slightly less likely in current smokers (OR 0.89, 95% CI: 0.80-0.99).
Fig. S1 1 shows the results in each registry, but not pooled estimates, because heterogeneity was too high (I 2 > 60%). Age at entry, age at diagnosis and Psoriasis Area and Severity Index (PASI) at entry were too heterogeneous among registries to be combined in the metaanalysis. Italian and Spanish patients on biologics had a PASI significantly higher at entry and were significantly younger at diagnosis than those receiving classic systemic therapies. Few registries reported measurements of body surface area (BSA) and Dermatology Life Quality , Ignacio GARCIA-DOVAL Patients with psoriatic arthritis or nail disease were more likely to receive biologics than classic therapies in almost all registries, but the results were heterogeneous despite the significant OR favouring the usage of biologics in most of them. In registries from Italy and Spain, patients with psoriasis different from plaque psoriasis were significantly more likely to receive conventional drugs.
DISCUSSION
In agreement with the findings of a previous PSO-NET analysis (1), the current study revealed that wide between-country heterogeneity exists in the distribution of covariates potentially influencing treatment selection (e.g. age, PASI and proportion with non-chronic plaque psoriasis). Beyond between registry variability, the current study found that some covariates are related per se with the odds of receiving a biologic or a classic treatment in most registries, e.g. BMI, psoriatic arthritis, nail disease or proportion of current smokers.
The strengths of this study are the increased power obtained from multiple registries compared with using each separately, the ability to describe and quantify between-country differences, and the use of a metaanalytical approach, in which each registry acts as its own control, which limits the risk of biases related to differences between registries. In addition, meta-analysis is a good way to define and quantify heterogeneity and to balance out differences in sizes among the registries.
Study limitations are: missing data from some registries, missing data on some predefined variables and that only univariate analysis was performed and we could not rule out that the factors we found as being associated with treatment choices were, in fact, intercorrelated and not independently associated with the treatment selection. A further limitation is that we could only analyse commonly measured and coded variables. Finally, the data were not updated. This delay is due to the extreme difficulty in combining data from different national registries. But because of the already high number of participants, we consider that this should not affect the results and overall conclusions.
Methodological differences might explain some of the differences found. This is probably the case for the heterogeneity of the percentage of patients with psoriatic arthritis or in PASI values. PASI values are also influenced by the lack of wash-out periods before starting a new therapy (leading to variability and PASI decrease) in real-world registries and by the fact that a minimum PASI is mandatory to prescribe biologics in some countries (possibly leading to a factitious increase). Single outlying results may also hide otherwise homogenous effects, e.g. only in the Danish registry is there no greatly increased use of biologics for psoriasis arthritis; thus, the otherwise highly significant prediction by psoriasis arthritis disappears.
Conclusion
Knowledge of the factors related to drug selection is important in order to plan statistical analysis of observational data (13) . Each registry could use this information to develop strategies for dealing with prescription bias, using methods such as propensity scores (14) . Identification of differences in the international usage of drugs can be useful for interpretation of observational studies (e.g. generalization of results) (15) , adds knowledge and understanding of different healthcare systems and might indicate areas for improvement in patient management. 
